Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
September 26, 2024 07:14 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...
Chronic Kidney Disease (CKD) Drugs Market is projected to reach USD 23.8 Billion, garnering a 4.2% CAGR from 2024 to 2034: Transparency Market Research, Inc.
September 24, 2024 08:32 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The global chronic kidney disease (CKD) drugs market (만성신장질환(CKD) 치료제 시장) was projected...
CEMATRIX Announces Project Delays
September 23, 2024 08:30 ET
|
CEMATRIX Corporation
CALGARY, Alberta, Sept. 23, 2024 (GLOBE NEWSWIRE) -- CEMATRIX Corporation (TSX: CEMX) (OTCQB: CTXXF) ("CEMATRIX" or the "Company") a North American leading manufacturer and supplier of...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024 08:10 ET
|
BioNTech SE
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron...
Existing-Home Sales Dipped 2.5% in August
September 19, 2024 10:00 ET
|
National Association of Realtors®
Washington, D.C., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Key Highlights Existing-home sales retreated 2.5% in August to a seasonally adjusted annual rate of 3.86 million. Sales slid 4.2% from...
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
September 16, 2024 08:45 ET
|
Ipsen Pharma
Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® (cabozantinib) versus placebo in advanced pancreatic and...
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
September 14, 2024 04:15 ET
|
Cullinan Therapeutics, Inc.
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion...
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
September 12, 2024 01:00 ET
|
Sanofi - Aventis Groupe
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, September 12, 2024....
Smith+Nephew brings pre-operative planning and accuracy to total ankle replacement with new TOTAL ANKLE Patient-Matched Guides
September 10, 2024 10:00 ET
|
Smith & Nephew UK Ltd
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its TOTAL ANKLE Patient-Matched Guides, giving surgeons a predictable and efficient option to help...
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
September 09, 2024 12:05 ET
|
ArriVent BioPharma, Inc.
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median...